Eli Lilly’s Results Signal Arrival of Blockbuster New Drug Class
Wall Street Journal
The company’s Alzheimer’s drug results might look better than Biogen’s, but both makers will likely benefit.
Wall Street Journal
The company’s Alzheimer’s drug results might look better than Biogen’s, but both makers will likely benefit.